Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424576 | 0.78 | PDE5A (0.44) | PNPPDE5APDE4APDE4BPDE4C | |
| SCHEMBL28671519 | 0.77 | CLPP (0.44) | PNPPDE5APDE4APDE4BPDE4C | |
| SCHEMBL22845413 | 0.73 | PDE1B (0.49) | PDE1BGAAMAPTCLPP | |
| SCHEMBL22410754 | 0.73 | P2RX3 (0.51) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22424242 | 0.70 | MAPT (0.44) | GAAALDH1A1POLBHTTMAPT | |
| SCHEMBL4411317 | 0.70 | CYP3A4 (0.45) | GAAALDH1A1CYP3A4CYP2C9MAPT | |
| SCHEMBL24914516 | 0.70 | CLPP (0.65) | PDE1BCYP3A4CLPP | |
| Acetic Acid SCHEMBL22717314 | 0.70 | PDE1B (0.46) | PDE1BALDH1A1MAPTKDM4ECLPP | |
| Hydrochloric Acid SCHEMBL3299132 | 0.70 | CYP3A4 (0.44) | GAAALDH1A1CYP3A4CYP2C9MAPT | |
| SCHEMBL9242016 | 0.69 | KDM4E (0.56) | PNPPDE5APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | PNP 63/4885PDE1B 3540/4885PDE5A 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.